Sökresultat
AstraZeneca presenterar många bröstcancerstudier i San Antonio
…e Vice President, Oncology R&D, said: “We are committed to transforming outcomes for women diagnosed or living with breast cancer by advancing a new generation of promising potential new medicines. The updates from the comprehensive DESTINY breast programme reflect the potential of Enhertu to help a wide range of breast cancer patients, while the encouraging data from the SERENA-1 Phase I trial paves the way for a clinical development programme to…
FDA godkänner Kisqali för att minska återfallsrisken vid tidig HR+/HER2- bröstcancer
…igator. “Today’s approval allows us to offer treatment with a CDK4/6 inhibitor to a significantly broader group of people as a powerful tool that, combined with endocrine therapy, can help further minimize their risk of cancer returning.” In EBC, Kisqali is taken with or without food as a once-daily oral dose of 400 mg (two 200 mg tablets) for three weeks, followed by one week off treatment, in combination with four weeks of any AI1. Patients shou…
Darolutamide plus ADT och docetaxel förlänger överlevnaden för patienter med metastaserad hormonkänslig prostatacancer
…is the only randomized, double-blind pivotal study prospectively designed to compare the use of a second-generation ARi plus ADT and docetaxel to ADT plus docetaxel (a guideline recommended standard-of-care) in mHSPC. Darolutamide is approved in more than 60 markets around the world, including the U.S., the European Union (EU), Japan and China, under the brand name Nubeqa®, for the treatment of patients with nmCRPC, who are at high risk of deve…
Ny subkutan beredning av Darzalex för behandling av multipelt myelom godkänd
…09 Last accessed May 2020. 10. ClinicalTrials.gov. Addition of daratumumab to combination of bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma. NCT02136134. Available at: https://clinicaltrials.gov/ct2/show/NCT02136134 Last accessed May 2020. 11. ClinicalTrials.gov. A study of combination of daratumumab and Velcade (bortezomib) melphalan-prednisone (DVMP) compared to Velcade melphalan-prednisone (VMP) in par…
SCANPROST 2023
…eatment of prostate cancer which has led to earlier treatment, improved outcomes and longer life for many patients. It is therefore our great pleasure to invite you to this years SCANPROST meetings to discuss and assess some of these recent developments. On behalf of the SCANPROST Scientific Steering Committee Gedske Daugaard, MD, PhD, Clinical Professor Department of Oncology, Rigshospitalet Michael Borre, Professor, Department Clinical Medicine…